

Anti-PCSK9 (Evolocumab), Human IgG2 Antibody

07/20

CATALOG NO.: A2168-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a human IgG2 monoclonal antibody that is directed against proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a serine protease that binds to LDL receptors on the hepatocyte cell surface and promotes the lysosome-mediated degradation of these receptors. This results in decreased uptake and clearance of LDL-C (bad cholesterol) by the receptors. The monoclonal antibody binds to PCSK9 and prevents interaction with the LDL receptor. This promotes the recycling of the internalized LDL receptor to the hepatocyte cell surface and increased removal of LDL-C from the blood. The original drug received approval from the FDA to treat homozygous and heterozygous familial cholesterolemia. The drug has also been approved to treat patients with high cholesterol, whose LDL-C was not controlled by the statin treatment.

ALTERNATE NAMES: AMG-145, AMG145, NN7415, FH3, PC9, FHCL3, NARC1, LDLCQ1, NARC-1, HCHOLA3

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG2, lambda

SOURCE: CHO cells

IMMUNOGEN: Human PCSK9

CAS NUMBER: 1256937-27-5

MOLECULAR WEIGHT: 144 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-1β (Canakinumab), Human IgG1 Antibody (A2144)
 Anti-PCSK9 (Alirocumab), Human IgG1 Antibody (A2153)
 Anti-TNF-α (Golimumab), Human IgG1 Antibody (A2141)
 Anti-IL-12β (Ustekinumab), Human IgG1 Antibody (A2137)
 Anti-TNFSF11 (Denosumab), Human IgG2 Antibody (A2150)

FOR RESEARCH USE ONLY! Not to be used on humans.